Benzbromarone Pharmacokinetics and Pharmacodynamics in Different Cytochrome P450 2C9 Genotypes

  • UCHIDA Shinya
    Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka
  • SHIMADA Kayoko
    Departments of Pharmacokinetics & Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
  • MISAKA Shingen
    Departments of Pharmacokinetics & Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
  • IMAI Hiromitsu
    Department of Clinical Pharmacology & Therapeutics, School of Medicine, Oita University
  • KATOH Yasuhiro
    Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka
  • INUI Naoki
    Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine
  • TAKEUCHI Kazuhiko
    Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine
  • ISHIZAKI Takashi
    Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine
  • YAMADA Shizuo
    Departments of Pharmacokinetics & Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
  • OHASHI Kyoichi
    Department of Clinical Pharmacology & Therapeutics, School of Medicine, Oita University
  • NAMIKI Noriyuki
    Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka
  • WATANABE Hiroshi
    Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine

Bibliographic Information

Other Title
  • Benzbromarone Pharmacokinetics and Pharmacodynamics in Différent Cytochrome P450 2C9 Genotypes

Search this article

Abstract

  Benzbromarone is a uricosuric drug and has been shown to be metabolized predominantly by cytochrome P450(CYP)2C9 in vitro findings. This study aims to investigate the influence of the CYP2C9 genotype on plasma levels of benzbromarone and 6-hydroxybenzbromarone, as well as uric acid lowering effects. A single oral dose pharmacokinetic and pharmacodynamic trial of benzbromarone (100 mg) was performed in 20 healthy volunteers, which included 15 with CYP2C9*1/*1, 4 with CYP2C9*1/*3, and 1 with CYP2C9*3/*3. The oral clearance of benzbromarone in the CYP2C9*1/*1 genotype and CYP2C9*1/*3 genotype was 58.8±25.2 L/hr/kg (mean±SD) and 51.3±7.9 L/hr/kg, respectively, whereas 8.58 L/hr/kg in the CYP2C9*3/*3 genotype. The metabolic ratio (6-hydroxybenzbromarone/benzbromarone) in urine was 38.6±10.7 in the CYP2C9*1/*1 genotype, 35.4±12.4 in the CYP2C9*1/*3 genotype and 12.9 in the CYP2C9*3/*3 genotype. Although benzbromarone significantly increased the urinary excretion and reduced the plasma concentration of uric acid, there were no significant differences in its effects for different CYP2C9 genotypes. These results suggest a critical role for CYP2C9 in the metabolism of benzbromarone in humans and a possible risk of toxicity in the CYP2C9*3 homozygote by lowering clearance of the drug. Further studies are required to assess the clinical impact of CYP2C9 on the metabolism of benzbromarone.<br>

Journal

Citations (5)*help

See more

References(46)*help

See more

Details 詳細情報について

Report a problem

Back to top